# Follistatin-344 (FST-344)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 4-5 (Early clinical trials + animal studies)
**Risk Profile:** MODERATE-HIGH (Complex cancer relationship, limited human data)

---

## What Is This?

Follistatin-344 is a protein that blocks myostatin — the hormone that limits muscle growth. By neutralising myostatin, follistatin theoretically allows muscles to grow beyond their normal limits. The concept is proven in animals (myostatin-knockout animals have 2-3x normal muscle), but multiple similar drugs have failed in human trials. It also has a complex relationship with cancer: it may reduce metastasis but potentially promote local tumour growth.

---

## Categories

`Muscle & Performance`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| Myostatin (GDF-8) | A protein that limits muscle growth — blocking it allows more muscle |
| Activin | A hormone that affects reproduction, metabolism, and tissue growth |
| TGF-β | Transforming Growth Factor-beta — a family of proteins controlling cell growth and fibrosis |
| BMPs | Bone Morphogenetic Proteins — signalling molecules for bone and tissue development |
| AAV | Adeno-Associated Virus — a harmless virus used to deliver genes in gene therapy |
| WADA | World Anti-Doping Agency — prohibits this substance in competitive sports |
| FS-315 | The circulating form of follistatin that the body produces from FS-344 |
| Metastasis | Cancer spread to distant organs |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Type | Activin-binding glycoprotein |
| Length | 344 amino acids (gene) → FS-315 circulating form |
| Molecular Weight | ~35 kDa |
| Primary Targets | Activin, Myostatin, TGF-β, BMPs |
| Mechanism | Irreversible ligand binding |
| Half-life | 12-15 hours (estimated) |
| FDA Status | Investigational (gene therapy trials) |
| WADA Status | Banned (S4.4 myostatin inhibitor) |

---

## Mechanism of Action

Follistatin-344 works by intercepting and neutralising members of the TGF-β superfamily — a group of signalling proteins that includes myostatin, the body's primary brake on muscle growth. When follistatin binds myostatin, it prevents the hormone from reaching its receptors, effectively releasing the brake and allowing greater muscle protein synthesis.

The mechanism extends beyond myostatin. Follistatin also binds activin (affecting gonadal function and metabolism), TGF-β itself (reducing fibrosis signalling), and bone morphogenetic proteins (altering bone and tissue development). This broad activity explains both its potential and its risks.

The FS-344 isoform specifically produces the FS-315 circulating form, which has reduced heparin affinity compared to other isoforms. This means less impact on the gonadal and pituitary axes and an improved safety profile for clinical use — important considerations given follistatin's broad activity.

### The Myostatin Story

The biology is compelling. Myostatin-knockout animals develop 2-3x normal muscle mass. Natural human mutations in myostatin produce exceptional muscularity. The famous "Belgian Blue" cattle carry a natural myostatin mutation that makes them extraordinarily muscular.

The problem is translation. Multiple pharmaceutical programs have attempted to block myostatin through various mechanisms. Most have failed in human trials. The path from dramatic animal results to human efficacy has proven difficult to traverse.

---

## Cancer Risk Assessment

### A Complex Relationship

Follistatin's relationship with cancer defies simple characterisation. It is aberrantly expressed in multiple solid tumours: gonadal cancers, gastric cancer, lung cancer, hepatocellular carcinoma, basal cell carcinoma, melanoma, oesophageal cancer, and prostate cancer. This pattern of expression in malignancies is concerning.

### The Dual Effect Paradox

Research reveals that follistatin has opposing effects on tumour behaviour. It may increase local tumour growth — a concerning finding. But it simultaneously may decrease metastasis and invasion — a protective finding. The mechanism appears to involve an energy trade-off: when cells shift away from migration and invasion, they can redirect resources toward growth and proliferation.

### Context-Dependent Effects

A HER2+ breast cancer study illustrated this complexity. Follistatin blocked activin-induced migration and completely prevented lung metastasis formation. Yet it had no impact on primary tumour growth. The net effect — promoting local growth while preventing spread — defies simple risk classification.

| Cancer Type | Follistatin Role |
|-------------|------------------|
| Breast (HER2+) | Potentially protective (anti-metastatic) |
| Esophageal | Potentially negative |
| Gastric | Potentially negative |
| Skin cancers | Potentially negative |
| Prostate | Potentially negative |

This context-dependence means the risk profile varies by individual cancer history and type.

---

## Clinical Development

The most promising follistatin work involves AAV gene therapy rather than injectable peptide. Trials at Nationwide Children's Hospital have delivered FS-344 cDNA via adeno-associated virus, producing the FS-315 circulating isoform. No serious adverse effects have been reported to date.

**Indications Under Study:**
- Duchenne muscular dystrophy
- Becker muscular dystrophy
- Inclusion body myositis
- Facioscapulohumeral dystrophy (FSHD)

These rare muscle diseases represent populations where the benefit-risk calculation differs substantially from healthy adults seeking muscle enhancement.

---

## The Trail of Failed Myostatin Inhibitors

Anyone considering follistatin should understand the history of this pathway in drug development.

| Compound | Mechanism | Outcome |
|----------|-----------|---------|
| ACE-031 | Activin receptor fusion | Failed - safety concerns |
| MYO-029 (Stamulumab) | Anti-myostatin antibody | Failed - no efficacy |
| Bimagrumab | Anti-ActRII antibody | Mixed results |
| LY2495655 | Anti-myostatin antibody | Failed |

Multiple well-funded programs targeting myostatin inhibition have failed to demonstrate robust human efficacy. This suggests either that the pathway doesn't translate from animals to humans as cleanly as hoped, or that the dosing and delivery challenges remain unsolved.

---

## Dosing (Research Context)

**No established human dosing for injectable follistatin peptide exists.**

### Empirical Protocols (NOT Trial-Validated)

| Protocol | Dose | Duration |
|----------|------|----------|
| Conservative | 50-100mcg | Daily x 10-20 days |
| Standard | 100mcg | Daily x 10-30 days |
| Loading | 100mcg | Daily x 10, then 2x/week |

Any results from injectable follistatin peptide are likely to be modest at best given the failed clinical programs. Short cycles with extended breaks are typically used, though continuous use safety is unknown.

### Cessation Rules

Discontinue immediately if any new skin lesion or mole changes appear, if tumour markers elevate (CEA, CA 19-9), if significant FSH/LH alterations occur, or if any signs concerning for malignancy develop.

---

## Contraindications

- Active or history of cancer (complex risk profile)
- Elevated tumour markers
- Family history of gonadal/GI cancers
- Reproductive concerns (affects activin/FSH)
- Pregnancy/breastfeeding
- Age <25

---

## Monitoring Protocol

| Test | Baseline | Ongoing | Rationale |
|------|----------|---------|-----------|
| Comprehensive metabolic panel | Yes | Monthly | Organ function |
| Testosterone, FSH, LH | Yes | Every 2-3 months | Gonadal axis |
| PSA (men) | Yes | Every 3 months | Prostate surveillance |
| CEA | Yes | Every 3-6 months | Colorectal marker |
| CA-125 (women) | Yes | Every 3-6 months | Ovarian surveillance |
| CA 19-9 | Yes | Every 3-6 months | GI cancer surveillance |
| Muscle mass (DEXA) | Yes | Every 3-6 months | Efficacy tracking |

### Tumour Marker Cessation Rule

**Any elevation in PSA, CEA, CA-125, or CA 19-9:** Immediate cessation of Follistatin-344 AND ALL growth factors (GH peptides, BPC-157, TB-500, GHK-Cu, Dihexa)

---

## Limitations

1. **Complex, context-dependent cancer relationship** — may promote local tumour growth
2. **Aberrant expression documented in multiple cancer types**
3. **Multiple myostatin inhibitor programs have failed** clinically
4. **Peptide quality highly variable** — difficult to verify
5. **Gene therapy approach more promising** than injectable peptide
6. **Limited human peptide data** — most evidence is gene therapy

---

## References

1. The Reign of Follistatin in Tumors and Their Microenvironment. PMC10887188. 2024.
2. Clinical and Therapeutic Implications of Follistatin in Solid Tumours. PMC5219916. 2017.
3. Inhibition of Myostatin with Emphasis on Follistatin as Therapy for Muscle Disease. PMC2717722. 2009.
4. Mendell JR, et al. Phase 1/2a follistatin gene therapy for Becker MD. Mol Ther. 2015.
5. ClinicalTrials.gov: AAV1-Follistatin gene therapy trials.
